Content

Welcome to the CJU website » LOG IN

Details

Should pathological T3 and/or margin positive prostate cancer receive adjuvant therapy? A radiation oncologists view
Department of Radiation Oncology, Toronto-Sunnybrook Regional Cancer Center, Uni
Jun 2000 (Vol. 7, Issue 3, Pages( 1043 - 1050)

Abstract

Text-Size + 

  • Patients with pathological stage T3 and/or margin positive prostate cancer after radical prostatectomy have a high risk of tumor recurrence, usually heralded by rising PSA. Adjuvant therapy such as radiotherapy and/or hormone therapy needs to be explored to provide a better outcome. To date the exact role and result of adjuvant therapy remains unclear. However there has been increasing suggestion that adjuvant radiotherapy improves local control and disease free survival. Also adjuvant hormone therapy may play a role in this group of patients with a high metastatic potential. This review article addresses the clinical significance of PT3 and/or margin positive prostate cancer and explores the rationale behind considering adjuvant therapy including postoperative radiotherapy and/or hormone therapy.

Current Issue

October 2019, Vol.26 No.5
canadian journal of urology